RecruitingNot ApplicableNCT07572903

The Efficacy and Safety of Temporal Interference Stimulation on Motor Symptoms of Parkinson's Disease

The Efficacy and Safety of Temporal Interference Stimulation on Motor Symptoms of Parkinson's Disease: A Three-arm, Randomized, Double-blind, Parallel-controlled Study


Sponsor

The First Affiliated Hospital of Anhui Medical University

Enrollment

90 participants

Start Date

May 6, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

This study aimed to observe the clinical efficacy and safety of single-target transcranial temporal stimulation (tTIS) intervention in Parkinson's disease (PD) patients and explore the neurophysiological mechanism of TIS intervention. The study was designed as a three-arm (A: GPi group, B: STN group, C: Sham group), randomized, double-blind, parallel-controlled trial. PD patients in the drug-off state (≥12 hours after drug withdrawal) were randomly assigned to receive either tTIS or sham stimulation targeting GPi/STN, with each stimulation lasting 30 minutes. Clinical symptom assessments were conducted before and after the intervention, and safety was monitored by researchers throughout the process.


Eligibility

Min Age: 40 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Temporal Interference Stimulation for people with parkinson's disease. The study is currently recruiting participants at 1 location. People eligible for this study include aged 40 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERTemporal Interference Stimulation

Temporal Interference Stimulation


Locations(1)

The First Affiliated Hospital of Anhui Medical University

Hefei, Anhui, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07572903


Related Trials